Recent Finacing
Recent Raise
RegCell develops an epigenetic, non‑genetic reprogramming platform to manufacture stable, antigen-specific regulatory T cells for restoring immune tolerance in autoimmune diseases and transplantation, with U.S. headquarters and Japanese R&D.
